Sarcosine (N-methylglycine) or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study

doi:10.1001/archpsyc.62.11.1196

機構典藏 > College of Sciences > Graduate Institute & Department of Mathematics > Journal Article > Item 987654321/41572

Please use this identifier to cite or link to this item: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/41572

Title:	Sarcosine (N-methylglycine) or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study
Authors:	Lane, Hsien-Yuan;Liu, Yi-Ching;Huang, Chieh-Liang;Chang, Yue-cune;Liau, Chun-Hui;Perng, Cheng-Hwang;Tsai, Guochuan E.
Contributors:	淡江大學數學學系
Keywords:	Glutamate;GlyT-1;N-methyl-D-aspartate;sarcosine;schizophrenia
Date:	2005-11-01
Issue Date:	2010-01-28 07:51:26 (UTC+8)
Publisher:	American Medical Association
Abstract:	Background: Small molecules that enhance the N-methyl-D-aspartate (NMDA) neurotransmission have been shown to be beneficial as adjuvant therapy for schizophrenia. Among these compounds, sarcosine (a glycine transporter-I inhibitor), when added to an existing regimen of antipsychotic drugs, has shown its efficacy for both chronically stable and acutely ill patients. However, the efficacy of these agents as a primary antipsychotic agent has not yet been demonstrated. Methods: Twenty acutely symptomatic drug-free patients with schizophrenia were randomly assigned under double-blind conditions to receive a 6-week trial of 2 g or 1 g of sarcosine daily. Results: Overall, patients in the 2-g group were more likely to respond as defined by a 20% or more reduction of the Positive and Negative Syndrome Scale total score, particularly among antipsychotic-naïve patients. However, there was no significant between-group difference in the sarcosine dose time interaction analysis. Both doses were well tolerated with minimal side effects. Conclusions: Although patients receiving the 2-g daily dose were more likely to respond, it requires further clarification whether the effect is limited to the antipsychotic-naive population. Future placebo- or active-controlled, larger-sized studies are needed to fully assess sarcosine’s effects.
Relation:	Archives of General Psychiatry 62, pp.1196-1204
DOI:	10.1001/archpsyc.62.11.1196
Appears in Collections:	[Graduate Institute & Department of Mathematics] Journal Article

Files in This Item:

File	Description	Size	Format
0006-3223_63(1)p9-12.pdf		84Kb	Adobe PDF	3	View/Open
index.html		0Kb	HTML	188	View/Open

Loading...